Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nektar Therapeutics ( (NKTR) ) has provided an announcement.
On April 20, 2026, Nektar Therapeutics reported 52-week topline data from the blinded 16-week extension of its Phase 2b REZOLVE-AA trial of rezpegaldesleukin in 92 patients with severe-to-very-severe alopecia areata, showing deepening responses with continued twice-monthly dosing. From week 36 to 52, 29% of low-dose and 31% of high-dose patients in the extension achieved new SALT scores of 20 or less versus none on placebo, and across the overall study population at week 52, rezpegaldesleukin more than doubled response rates versus placebo on multiple SALT thresholds, supporting advancement into late-stage development.
Investigators highlighted that the T regulatory cell-based mechanism appears to deliver increasing clinical benefit over time and may offer a safer alternative to JAK inhibitors, potentially positioning rezpegaldesleukin as a first-line systemic biologic for alopecia areata. Safety remained favorable and consistent with prior studies, with 94% of extension patients completing the full 52 weeks, mostly mild-to-moderate injection-site reactions, and no discontinuations in the extension due to treatment-emergent adverse events, underscoring the drug’s potential appeal to clinicians and patients in a market with significant unmet need.
The most recent analyst rating on (NKTR) stock is a Buy with a $123.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
The score is held back primarily by weak financial performance (recurring losses, declining 2025 revenue, and substantial cash burn). Offsetting this, technicals are strong with price well above key moving averages and supportive momentum, while the latest earnings call was positive on clinical progress and funding (enabling Phase 3) but tempered by higher 2026 spending guidance and execution risk.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing novel immunology therapies, including the first-in-class IL-2 pathway agonist and regulatory T-cell biologic rezpegaldesleukin. The drug is being advanced as a self-administered injection for multiple autoimmune and inflammatory diseases such as atopic dermatitis, alopecia areata and Type 1 diabetes, and is wholly owned by Nektar Therapeutics.
Average Trading Volume: 1,109,388
Technical Sentiment Signal: Buy
Current Market Cap: $2.39B
Learn more about NKTR stock on TipRanks’ Stock Analysis page.